BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

BMO Capital raised the firm’s price target on Schrodinger (SDGR) to $28 from $25 and keeps an Outperform rating on the shares. The ...

Mizuho raised the firm’s price target on Alkermes (ALKS) to $40 from $35 and keeps an Outperform rating on the shares. The firm assessed ...

In another delay for the psychedelic treatment space, Compass Pathways announced adjusted timelines for two Phase III trials ...

Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, ...

These trials are expected to launch in the first half of 2025, with data readouts expected by year-end. With Phase 2 data for UNVEIL-IT trial also anticipated by the close of 2025, GENFIT will deliver ...

The decision to reduce the company's workforce and pause other pipeline activities to focus entirely on COMP360 has been ...

The new Passport stands as Honda's most aggressive off-road SUV with a handsome redesign, rugged upgrades, and an optional ...

China’s upcoming H-20 Xi’an stealth bomber has the U.S. concerned, with capabilities that could rival the B-2 Spirit and even ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning, and welcome to the Axsome Therapeutics Third ...

Financially stable C4 Therapeutics (CCCC) is worth watching for patient investors, but current lack of definitive data poses ...

T he Honda Passport is returning to its roots. The original 1990s Passport was an Isuzu-based SUV with some serious off-road ...